Diamond, Michael S. http://orcid.org/0000-0002-8791-3165
Lambris, John D. http://orcid.org/0000-0002-9370-5776
Ting, Jenny P. http://orcid.org/0000-0002-7846-0395
Tsang, John S. http://orcid.org/0000-0003-3186-3047
Article History
Accepted: 10 May 2022
First Online: 4 July 2022
Competing interests
: M.S.D. is a consultant for Inbios, Vir Biotechnology, and Carnival Corporation and is on the Scientific Advisory Boards of Moderna and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Moderna and Emergent BioSolutions. J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for therapeutic purposes; is the inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are being developed by Amyndas Pharmaceuticals; is the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (Cp05/POT-4/APL-1 and PEGylated derivatives such as APL-2/pegcetacoplan and APL-9). The other authors declare no competing interests.
Free to read: This content has been made available to all.